Addendum: Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition

PDF  |  How to cite

Oncotarget. 2022; 13:1216-1216. https://doi.org/10.18632/oncotarget.28293

Metrics: PDF 456 views  |   ?  

Marcel Kemper1,2,*, Georg Evers1,2,*, Arik Bernard Schulze1,2, Jan Sperveslage3, Christoph Schülke4, Georg Lenz1,2, Thomas Herold5, Wolfgang Hartmann3, Hans-Ulrich Schildhaus2,5,# and Annalen Bleckmann1,2,6,#

1Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Muenster, 48149 Muenster, Germany
2West German Cancer Center, Sites Muenster & Essen, 45147 Essen, Germany
3Gerhard-Domagk-Institute of Pathology, University Hospital Muenster, 48149 Muenster, Germany
4Institute of Clinical Radiology, University Hospital Muenster, 48149 Muenster, Germany
5Institute of Pathology, University Hospital Essen, 45147 Essen, Germany
6Department of Hematology/Medical Oncology, University Medical Center Goettingen, 37075 Goettingen, Germany
*Authors share first authorship
#Authors share last authorship

Published: November 2, 2022

Copyright: © 2022 Kemper et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: The authors obtained written informed consent from the patient to publish information and images.

Original article: Oncotarget. 2021; 12:1946–1952. DOI: https://doi.org/10.18632/oncotarget.28062

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28293